Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Immune Checkpoint Inhibitors Market Report 2026-2030 with Detailed Company Profiles, Grant Analyses, Partnership Evaluations and More

globenewswire.com
BMY Mentioned as a key industry player in the growing immune checkpoint inhibitors market, which is projected to expand significantly. The article does not provide specific positive or negative commentary on the company itself. GSK Listed as a key industry player in the expanding immune checkpoint inhibitors market. The article focuses on market growth and trends rather than specific company performance. INCY Identified as a key industry player within the immune checkpoint inhibitors market. The article's focus is on the overall market growth and therapeutic advancements, not on Incyte's specific performance. NVS Included as a key industry player in the immune checkpoint inhibitors market report. The article highlights market growth and trends, without specific sentiment towards Novartis.

Immune Checkpoint Inhibitors Market Report 2026-2030 with Detailed Company Profiles, Grant Analyses, Partnership Evaluations and More Dublin, April 20, 2026 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market: Industry Trends and Global Forecasts, till 2030" has been added to ResearchAndMarkets.com's offering.

The immune checkpoint inhibitors market, valued at USD 62 billion currently, is projected to reach USD 246 billion by 2035, with a strong CAGR of 14.7% during the forecast period. This growth is driven by multiple factors such as advancements in cancer therapeutics and increasing cancer incidence worldwide.

Segmentation and Analysis

The market is segmented based on immune checkpoint proteins, target disease indications, therapeutic modalities, routes of administration, and geographical regions.

Growth and Trends

Cancer remains a leading cause of death globally, with the WHO estimating a 70% rise in new cases in the next 20 years. Traditional treatments suffer from limitations in advanced cancer stages, while immune checkpoint therapies provide a new avenue of treatment by preventing tumors from circumventing immune responses. Immune checkpoint inhibitors like Yervoy (ipilimumab) have marked a significant breakthrough. Despite the effectiveness of current PD-1/PD-L1 inhibitors, resistance remains a challenge in specific patient populations.

Advancements in research have identified additional inhibitory and stimulatory receptors, which are in use for developing next-generation therapies. There is growing interest in combinatorial therapies that leverage immune checkpoint blockades and co-stimulatory signals, showing potential in treating autoimmune diseases as well.

Market Insights

Key findings highlight the importance of clinical trial designs that drive successful therapeutic outcomes. Over 3,600 trials worldwide have focused on PD-1/PD-L1 targeting immune checkpoint inhibitors, noted in more than 450 scientific articles. New molecular entity trials aim to improve treatment response, focusing on long-term outcomes and toxicity management across diverse patient groups.

Key Industry Players: Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Novartis, Trillium Therapeutics.

Research Coverage and Market Opportunities:

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this report visit https://www.researchandmarkets.com/r/9lz8dj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.